No surprise: Repatha reality is messier than initial reports suggested
Whiplash warning! Readers brace for possible neck injury as competing claims on statins hit the headlines
With clout growing, hospitals avoid negative coverage of huge fines, safety violations
Coverage of Amarin off-label promotion agreement should have acknowledged deadly history of such marketing
Journalists need to scrutinize the USPSTF’s draft recommendations on statins … and so do patients
Informed patients need one thing not provided in SPRINT trial news: what were the absolute benefit/harm numbers?
Do published SPRINT study results live up to premature NIH news release hype?
NIH, news media, need to slow down on the SPRINT hype
MD gets direct mail about screening – says she “can’t stand this anymore” a la Howard Beale
Coverage of FDA’s trans fat decision a high-water mark for health journalism